Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -9.94% | -2.36% | |||
| Gross Profit | 9.94% | 2.36% | |||
| SG&A Expenses | 2.07% | -0.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.30% | -1.73% | |||
| Operating Income | 6.30% | 1.73% | |||
| Income Before Tax | -4.05% | 8.26% | |||
| Income Tax Expenses | -40.63% | -49.21% | |||
| Earnings from Continuing Operations | -3.80% | 8.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.80% | 8.68% | |||
| EBIT | 6.30% | 1.73% | |||
| EBITDA | 6.35% | 1.71% | |||
| EPS Basic | -6.10% | 11.35% | |||
| Normalized Basic EPS | -6.37% | 10.92% | |||
| EPS Diluted | -6.10% | 11.35% | |||
| Normalized Diluted EPS | -6.37% | 10.92% | |||
| Average Basic Shares Outstanding | -2.27% | 3.26% | |||
| Average Diluted Shares Outstanding | -2.27% | 3.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||